+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 85Years
All Genders
ID05532059

Phase 2 Study of Lenvatinib and Tislelizumab with Gemcitabine and Cisplatin for Advanced Cholangiocarcinoma

Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2025-02-10

100

Participants Needed

1

Research Sites

156 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of a combination treatment using lenvatinib, tislelizumab, gemcitabine, and cisplatin GPLET in patients with advanced cholangiocarcinoma, a group of aggressive cancers arising from bile duct cells. This phase 2, open-label study aims to investigate how this combination impacts tumor response and survival compared to gemcitabine plus cisplatin alone. The rationale is based on the potential for these drugs to enhance the immune systems ability to fight cancer by reducing tumor immunosuppression and triggering strong anti-tumor T cell responses. Participants receive intravenous gemcitabine and cisplatin on days 1 and 8 of each 21-day cycle. Those in the experimental group also take oral lenvatinib daily 8 mg if under 60 kg or 12 mg if 60 kg or more from days 1 to 21, and receive an intravenous dose of tislelizumab on day 15. The control group receives only gemcitabine and cisplatin. Treatment cycles repeat every 21 days, and the study monitors patients through multiple cycles. During the study, participants will undergo evaluations of tumor response after four treatment cycles to measure objective remission rate. Researchers will also track progression-free survival and overall survival for up to 60 months. Safety assessments and regular monitoring of organ and bone marrow function are included. The total study duration allows for long-term follow-up to understand the treatments impact on disease progression and patient outcomes.

CONDITIONS

Brief Title

Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here